ImmunityBio, Rafa win Israeli approval for ANKTIVA plus BCG in bladder cancer
IBRX•Israel’s Ministry of Health approved ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, and Rafa was named exclusive commercialisation partner in Israel.
1. Israeli approval
ImmunityBio and Rafa announced that Israel’s Ministry of Health approved ANKTIVA plus BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ. Rafa was named the exclusive commercialisation partner for ANKTIVA in Israel.
